ClinicalTrials.gg
CompletedNCT04256707SPRINTUpdated Oct 9, 2026Results posted

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

A Phase 1/2 interventional study of Selinexor 100 mg and Docetaxel in Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) and Other Solid Tumors, sponsored by Karyopharm Therapeutics Inc. Completed at 11 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Karyopharm Therapeutics Inc · Phase 1/2, Interventional, and Treatment

Updated Oct 9, 2026Results postedStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 222 studies in Carcinoma, Non-Small-Cell Lung with a site in Israel — 47 open to participants now, 95 under way, 44 of them phase 3. Carcinoma, Non-Small-Cell Lung · Israel.

Enrollment
167th of 206
80 · median 329
Started
2020
with 19 others
Phase 1/2
20 of 222
5 open now
Registered
127th of 222
by date

Among the 222 studies in Carcinoma, Non-Small-Cell Lung with a site in Israel, this one is the 167th largest by enrollment of the 206 interventional ones that give a count, is one of 20 that started in 2020, is one of 20 in phase 1/2, and was the 127th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

47 of the 222 studies in Carcinoma, Non-Small-Cell Lung with a site in Israel are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 222 studies in Carcinoma, Non-Small-Cell Lung with a site in Israel, or all of them as a file.
02

Study summary

This is a Phase 1/2, two-part, multi-arm, open-label study in patients with normal Hepatic Function (HF), with either Non-small cell lung cancer (NSCLC), who have had 1-2 prior lines of treatment, with 1 line containing a checkpoint Inhibitor (CPI); or patients with normal HF, with colorectal cancer (CRC) who have had 1-3 prior lines (KRAS wild-type [WT]) or 1-2 prior lines (mutant KRAS) of treatment with no CPI; or patients with impaired HF, with any solid tumor, who have had at least 1 prior line of treatment.

The study will comprise 2 treatment periods (monotherapy and combination therapy).

The purposes of this study, during Monotherapy period, are: (1) to determine the relative bioavailability of the 100 milligrams (mg) (Tablet B) and 20 mg (Tablet A) tablets of selinexor at 100 mg once weekly (QW) dose in patients with normal hepatic function; and (2) to assess the PK of selinexor after a single dose of 40 mg (2 × 20 mg), among patients with moderate and severe hepatic impairment, relative to 100 mg (5 × 20 mg), among patients with normal hepatic function; and, during the Combination therapy period, to assess the preliminary anti-tumor activity of selinexor in combination with docetaxel in patients with NSCLC and with pembrolizumab or folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI) in patients with CRC.

Read the detailed description

Up to 120 patients will be enrolled, of which, 20 with normal HF will be able to continue from Monotherapy to Combination therapy and up to 106 patients with normal HF will receive combination therapy in total. Patients with impaired hepatic function can only participate in the Monotherapy part of the study.

Monotherapy Period:

For the Monotherapy Period of Study KCP-330-027, patients with normal hepatic function (n=20), will be allocated to one of two test formulation treatment arms, and will receive a cross-over once weekly oral dosing, with either 1x100 mg or 5x20 mg selinexor, for 2 weeks, and then will have the option to move on to the combination treatment part of the study. Patients with either moderately or severely impaired hepatic functions will be treated with 2x20 mg selinexor weekly (with an option to increase the dose every 3 weeks by 20 mg increments, up to 80 mg).

For the assessment of hepatic impairment, participants with any type of advanced or metastatic solid tumor who have moderate or severe hepatic impairment will be enrolled in Moderate Hepatic Impairment (MHI) (n=8) and Severe Hepatic Impairment (SHI) (n=6) arms, respectively and will be treated with 2 × 20 mg selinexor, weekly.

For Weeks 1 and 2, following an overnight fast of at least 10 hours, patients will be fed a standard low-fat meal 30 minutes prior to administration of once weekly selinexor. Patients should finish the meal in 30 minutes or less; however, selinexor dose should be administered 30 minutes after start of the meal.

Blood sampling for selinexor PK analyses will be collected ≤10 minutes (m) pre selinexor dose, and at 15m (±5m), 30m (±5m), 1 hour (h) (±5m), 1.5h (±5m), 2h (±10m), 3h (±10m), 4h (±10m), 5h (±10m), 6h (±10m), 8h (±20m), 10h (±20m; optional), 24h (±1h), 30h (±1h), and 48h (±2h) post selinexor dose. Practitioners must record the actual clock time for selinexor dose, and each sample drawn.

If a patient experiences emesis during the first 6 hours of the PK sampling, the PK results for that week will be excluded from the PK analysis dataset, and all testing timepoints must be re-collected during the following week (in this case, the same dosing formulation should be repeated on the following week, and other dosing formulation will be given the week after that).

Patients who will complete the Monotherapy Period will be reassessed for continuation to the Combination Therapy Period, as long as their Hepatic Function remains normal.

If a patient experiences significant toxicity related to selinexor and can't start the combination therapy immediately following monotherapy, dose interruption and weekly retesting are allowed for up to 21 days after the end of Monotherapy treatment visit. Patients requiring >21 days to recover from toxicities related to selinexor should be discussed with the Sponsor's Medical Monitor for documented approval to continue to the Combination Therapy Period. Reassessment may be extended then and following Medical Monitor approval up to 28 days.

Combination Therapy Period:

In the combination treatment period of the study, patients with normal hepatic functions will be allocated to one of 3 arms (with Arm C divided into 2 cohorts): Arm A (n= up to 40): Patients with NSCLC who have had up to 2 lines of prior systemic treatment with 1 line containing a CPI will receive 60 mg selinexor weekly, in combination with docetaxel 75 milligrams per meter square (mg/m\^2) once every 3 weeks; Arm B (n= up to 40): Patients with CRC (KRAS WT) who have had up to 3 lines of prior systemic treatment or patients with CRC (KRAS mutant [KRAS Mut]) who have had up to 2 lines of prior systemic treatment, with no lines containing a checkpoint inhibitor (CPI) will receive 80 mg selinexor weekly, in combination with pembrolizumab 200 mg once every 3 weeks; Arm C (n\<=26): Patients with CRC (regardless of KRAS status) who have had up to 2 lines of prior systemic treatment (regardless of CPI use) will receive either: (Cohort 1) selinexor 40 mg on days 1, 3, 15 and 18 in 28-day cycle + FOLFIRI; or (Cohort 2) selinexor 80 mg on days 1 and 15 in 28-day cycle + FOLFIRI.

Combination Therapy Period Patients will receive combination treatment until progressive disease (PD) or intolerable toxicity.

During both study periods, safety will be assessed through continuous reporting of adverse events (AEs), treatment-emergent adverse events (TEAEs), regularly scheduled clinical laboratory tests (hematologic and chemical), and physical examinations.

Tumor assessment will be performed with either computed tomography (CT) or magnetic resonance imaging (MRI) (CT with contrast preferred; for each patient, the imaging method should remain the same throughout the study).

Following treatment, patients will come in for a safety visit (approximately 30 days after the last dose of combination therapy) and will be followed for up to 2 years after that. Patients who discontinued due to PD will be followed for survival, and patients who discontinued for reasons other than PD will have tumor assessments until PD or until the start of new anti-neoplastic therapy, after which they will be followed for survival.

03

Conditions studied

  • Non-Small Cell Lung Carcinoma (NSCLC)
  • Colorectal Cancer (CRC)
  • Other Solid Tumors

Keywords

  • Non-small cell lung carcinoma
  • Selinexor
  • Docetaxel
  • Colorectal cancer
  • KPT-330
  • Bioequivalence
  • Relative bioavailability
  • Pharmacokinetics
  • Other Solid Tumors
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Common inclusion criteria for all patients:

  1. Are greater than or equal to [≥] 18 years of age at the time of .
  2. Have confirmed solid tumor (any type of advanced or solid tumor for the Hepatic Impairment Arm of the Monotherapy Part), advanced or metastatic NSCLC or CRC and evidence of per (RECIST v1.1 or criteria, as applicable).
  3. Willing to provide written informed consent in accordance with federal, local, and institutional guidelines and comply with all requirements of the study.
  4. Female patients of must have a negative serum pregnancy test at screening and agree to use highly effective (dual methods of) throughout the study and for 4 months following the last dose of study drug (childbearing potential excludes: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy or hysterectomy); and male patients must use an effective barrier method of contraception throughout the study and for 4 months following the last dose of study drug if sexually active. Male patients must agree not to donate sperm during the study treatment period.

    For the Monotherapy Part only (bioavailability/bioequivalence [BA/BE] and hepatic impairment [HI] arms):

  5. Have received at least 1 line of systemic anticancer treatment unless there is no standard of care therapy or standard of care therapy is ( or neoadjuvant therapy is not counted as one line of systemic therapy). Patients must have failed prior standard curative therapy for their disease, must be intolerant to or be ineligible for any potentially curative approved treatment, irrespective of line of therapy.
  6. Must have either normal hepatic function, or moderate or severe hepatic impairment (as defined by the NCI organ dysfunction working group (NCI-ODWG) criteria:

    1. S20-100 and S100-20 arms: normal hepatic function (total and [AST] less than or equal to [≤] [ULN]).

      Note: Patients with mild hepatic dysfunction (total bilirubin greater than [>] 1 to 1.5 × ULN or AST > ULN) may be included if liver function tests are stable for the past 3 months and enrollment is approved in writing by the Sponsor's Medical Monitor.

    2. MHI arm: ≥1 week of documented moderate hepatic impairment (total bilirubin >1.5-3 × ULN, any level of AST).
    3. SHI arm: ≥1 week of documented severe hepatic impairment (total bilirubin >3-10 × ULN, any level of AST).

    For Combination Therapy Part only:

  7. Previous treatment lines (adjuvant or neoadjuvant therapy is not counted as one line of systemic therapy):

    1. Arm A: For patients with NSCLC, have received 1-2 prior lines of systemic anti-cancer treatment with 1 regimen including an /L1 monoclonal antibody (mAb)
    2. Arm B: For patients with RAS mutant CRC, 1-2 prior lines of systemic treatments, and no prior anti- programmed cell death protein 1/L1 monoclonal antibody (anti-PD-1/L1 mAb).

      • KRAS WT: have 1-3 prior lines of systemic treatments.
      • KRAS mutant (at least 50 percent [%] of patients): 1-2 prior lines of systemic treatments.
    3. Arm C: For patients with CRC participating in the combination arm with FOLFIRI, 1-2 prior lines of systemic therapy are allowed.
    4. Arm B and C in CRC: patient with CRC who are not candidates for curative resection of metastatic lesions.
  8. Must have hepatic function as follows:

    1. Arm A (combination with docetaxel): Patients with NSCLC who are to receive docetaxel and have bilirubin ≤ ULN, and AST and/or alanine transaminase (ALT) ≤ 1.5 x ULN.
    2. Arm B and C: total bilirubin ≤ 1.5 × ULN and AST ≤ 2.5 x ULN, AST ≤ 2.5 x ULN; for Arm B, unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin must be ≤ 4 x ULN.

Key Exclusion Criteria:

Common exclusion criteria for all patients:

  1. Have inadequate hematopoietic function defined as (without transfusion or growth factor support within 7 days prior to first dose):

    1. For S20-100 or S100-20 arms: (ANC) \<1.5 × 10\^9/liter (L); count (PLT) \<100 × 10\^9/L; or (Hb) \<10 gram per deciliter (g/dL).
    2. For Arms A-C: ANC \<1.5 × 10\^9/L; PLT \<100 × 10\^9/L; or Hb \<10 g/dL.
  2. Have inadequate renal function defined as a calculated (CrCl) of: a. all patients: \<20 mL/min using the formula of Cockcroft and Gault.
  3. Have any other medical condition especially any gastrointestinal (GI) dysfunctions or GI disease that could interfere with the absorption of selinexor (e.g., inability to swallow or retain oral medications, malabsorption syndrome, a history of GI surgery which may result in intestinal blind loop, significant gastroparesis, unresolved nausea, vomiting, or diarrhea [National Cancer Institute (NCI) (CTCAE) Grade >1]).
  4. Ongoing infection requiring parenteral antibiotics, antivirals, or antifungals on Day 1 dosing.

    a. All patients: on Day 1 dosing.

  5. Prior exposure to a SINE compound or selinexor.
  6. Insufficient time since or not recovered from procedures or anti-cancer therapy, defined as:

    1. Not recovered from major surgery ≤21 days for Arms A, B, and C prior to Day 1 dosing. Minor procedures, such as , dental work, or placement of a port or intravenous (IV) line for infusion are permitted.
    2. Have ongoing anti-cancer therapy-related toxicities CTCAE Grade >1. Patients with any of the following will not be excluded: immune checkpoint-related endocrinopathies that are well controlled with hormonal supplements, patients with electrolyte abnormalities that are well-managed with supplementation, patients with Grade 2 lymphopenia, or patients with alopecia of any grade. In specific cases, patients whose toxicity has stabilized or with Grade 2 non-hematologic toxicities can be allowed following documented approval by the Sponsor's Medical Monitor.
    3. Had last dose of previous anti-cancer therapy ≤14 days prior to Day 1 dosing.
    4. Palliative radiotherapy >14 days prior to the study is allowed.
    5. Received drugs in other clinical trials within 28 days, or 5 half-lives of the investigational drug (whichever is shorter), prior to Cycle 1 Day 1 (C1D1).
  7. Serious active psychiatric or active medical condition that could interfere with participation in the study or in the opinion of the Investigator would make study involvement unreasonably hazardous for Arms A-C.
  8. Known allergy to selinexor (all patients), docetaxel (NSCLC Arm A only), pembrolizumab (CRC arm B only), 5-FU, leucovorin, or irinotecan (CRC Arm C only).
  9. Female patients who are pregnant or breastfeeding.

    For Monotherapy Part only (BA/BE and HI arms):

  10. Have an (ECOG) performance status of:

    1. ≥3 for patients to be enrolled into the S20-100 or S100-20 arms of the study.
    2. ≥4 for patients to be enrolled into the MHI and SHI arms of the study.
  11. For MHI and SHI arms: ANC \<1 × 10\^9/L; PLT \<75 × 10\^9/L; or Hb \<8 g/dL.
  12. Received strong cytochrome P450 3A () inhibitors ≤7 days prior to Day 1 dosing OR strong CYP3A inducers ≤14 days prior to Day 1 dosing.
  13. Inability or unwillingness to undergo a series of PK sampling.

    For Combination Therapy Part only:

  14. Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≥3 for Arms A and B and ECOG PS ≥2 for Arm C.
  15. Arm B patients with CRC who are to receive pembrolizumab:

    1. Had a diagnosis of immunodeficiency or are receiving systemic therapy (>10 milligram per day [mg/day] of prednisone or equivalent) or any other form of therapy.
    2. Patients with controlled diabetes mellitus and patients with endocrinopathies on stable hormone replacement therapy, are eligible for the trial.
    3. Have active disease requiring systemic treatment during the past 2 years. Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted.

      Note: The Investigator needs to evaluate the patient's medical history to confirm that they are eligible to receive the combination with pembrolizumab per these criteria.

    4. For patients with CRC who have received against an infectious disease (e.g., nasal spray influenza vaccine) ≤14 days prior to the intended C1D1 of the Combination Therapy.
  16. Arm C: Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Note: for patients who are initially enrolled onto the BA/BE arm in the monotherapy part and plan to switch to combination therapy after completing the planned dosing and PK sample collection, dose interruption between the Monotherapy Part and the Combination Therapy Part is allowed for recovery from AEs. Patients requiring >21 days to recover from toxicities related to selinexor should be discussed with the Sponsor's Medical Monitor for documented approval to continue to the Combination Therapy Part if inclusion/exclusion criteria are met. Experiencing PD during the Monotherapy Part does not constitute exclusion from the Combination Therapy Part.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Monotherapy: Normal Hepatic Function (Selinexor)

    (Closed for Enrollment) S20-100 arm: * Week 1: selinexor 5 x 20-mg tablet once weekly (QW). * Week 2: selinexor 1 x 100-mg tablet QW. S100-20 arm: * Week 1: selinexor 1 x 100-mg tablet QW. * Week 2: selinexor 5 x 20-mg tablet QW.

    Drug: Selinexor 100 mg

  • Experimental
    Monotherapy: Impaired Hepatic Function (Selinexor)

    Cohort 1: Patients with Moderate Hepatic Impairment with any Solid Tumors. - Selinexor 2 x 20-mg tablet QW. Cohort 2: Patients with Severe Hepatic Impairment with any Solid Tumors. \- Selinexor 2 x 20-mg tablet QW.

    Drug: Selinexor 40 mg

  • Experimental
    Combination Therapy: NSCLC Arm A: (Selinexor + Docetaxel)

    (Closed for Enrollment) Selinexor 60 mg oral dose QW and docetaxel 75 mg/m\^2 intravenously (IV) once every 3 weeks (non-small cell lung cancer \[NSCLC\] patients).

    Drug: Docetaxel · Drug: Selinexor 60 mg

  • Experimental
    Combination Therapy: CRC Arm B: (Selinexor + Pembrolizumab)

    (Closed for Enrollment) Selinexor 80 mg oral dose QW and pembrolizumab 200 mg IV every 3 weeks (Colorectal cancer \[CRC\] Patients).

    Drug: Pembrolizumab · Drug: Selinexor 80 mg

  • Experimental
    Combination Therapy: CRC Arm C: (Selinexor + FOLFIRI)

    (Closed for Enrollment) Cohort 1: Selinexor 40 mg oral dose Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5- fluorouracil (5-FU) 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients). Cohort 2: Selinexor 80 mg oral dose Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5-FU 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients).

    Drug: FOLFIRI · Drug: Selinexor 40 mg · Drug: Selinexor 80 mg

Interventions

  • 100-mg 2 formulations: * 5 × 20-mg tablets (Tablet A) * 1 × 100-mg tablet (Tablet B)

    Also known as: Xpovio®

  • 75 mg/m\^2 IV

    Also known as: Taxotere®

  • 200 mg IV

    Also known as: Keytruda®

  • DrugFOLFIRI

    FOLFIRI: * Irinotecan 180 mg/m\^2 * Leucovorin 400 mg/m\^2 * 5-FU 400 mg/m\^2 bolus * 5-FU 2400 mg/m\^2 IV

  • \- 2 × 20-mg tablets (Tablet A)

    Also known as: Xpovio®

  • \- 4 × 20-mg tablets (Tablet A)

    Also known as: Xpovio®

  • \- 3× 20-mg tablets (Tablet A)

    Also known as: Xpovio®

06

What researchers measure

Primary outcomes

  1. Monotherapy: Area Under the Concentration-Time Curve From Time Zero to Time of Last Concentration (AUC 0-t) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

    AUC0-t was defined as the total-drug area under the concentration-time curve from time zero to time of last concentration measured.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  2. Monotherapy: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-Inf) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

    AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated), calculated as AUC0-last + Ct/λ, where: Ct = the last quantifiable concentration and λ is terminal elimination rate constant.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  3. Monotherapy: Maximum Plasma Concentration (Cmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

    Cmax was defined as maximum observed plasma total-drug concentration of selinexor.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  4. Combination Therapy (Arms: A and B): Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    Overall response rate (ORR) was defined as the percentage of participants who achieved an Investigator-determined best overall response (BOR) of partial response (PR) or complete response (CR) as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants who achieved ORR were reported.

    Time frame: Up to 25 months

  5. Combination Therapy (Arm C): Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Adverse event (AE): Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.

    Time frame: From start of study drug administration up to survival follow-up (up to 25 months)

Secondary outcomes

  1. Monotherapy: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

    Tmax was defined as time to the maximum observed concentration of selinexor.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  2. Monotherapy: Terminal Elimination Rate Constant (Lambda z) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

    Lambda z was defined as the terminal elimination rate constant of selinexor.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  3. Monotherapy: Terminal Half-Life (t1/2) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

    t1/2 was defined as the terminal elimination half-life of selinexor.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  4. Monotherapy: Apparent Clearance (CL/F) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

    CL/F was defined as the apparent clearance of selinexor.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  5. Monotherapy: Apparent Volume of Distribution (Vd/F) of Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

    Vd/f was defined as the apparent volume of distribution, calculated as Dose/ (λz\*AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  6. Monotherapy: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma Protein

    Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. Mean percent fraction unbound of selinexor (Tablet A) in plasma, calculated by averaging the percent fraction unbound measurements obtained at 3 and 8 hours post-dose on Days 1 and 8.

    Time frame: At 3 and 8 hours post-dose on Days 1 and 8

  7. Monotherapy: Maximum Free-Drug Concentration (Cmax,u) of Free Selinexor (Tablet A) in Plasma

    Cmax,u was defined as the maximum observed free-drug concentration of Selinexor, calculated as Cmax \* Fu.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  8. Monotherapy: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Free Selinexor (Tablet A) in Plasma

    AUCu was defined as free-drug area under the concentration-time curve from time zero to infinity (extrapolated), calculated as (AUC0-last + Ct/λz) \* Fu, where: Ct = the last observed nonzero concentration.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  9. Monotherapy: Apparent Free-drug Clearance (CLu/F) of Free Selinexor (Tablet A) in Plasma

    CLu/F was defined as the apparent free-drug clearance of selinexor.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  10. Monotherapy: Apparent Free-drug Volume of Distribution (Vu/F) of Free Selinexor (Tablet A) in Plasma

    Vu/F was defined as the apparent free-drug volume of distribution of selinexor.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8

  11. Combination Therapy (Arms: A, B and C): Progression-free Survival (PFS)

    PFS was defined as the time from the starting date of the combination therapy until the date of first progressive disease (PD) determined by PI per Response Evaluation Criteria in Solid Tumors (RECIST) for Arm A and B or Immunotherapeutic Response Evaluation Criteria in Solid Tumors (iRECIST) for Arm C, or death due to any cause, whichever occurred first.

    Time frame: Time from starting date of combination therapy until the date of first PD or death due to any case, whichever occurs first (up to 25 months)

  12. Combination Therapy (Arms: A, B and C): Duration of Response (DOR)

    DOR was defined for participants with partial response (PR) or complete response (CR) as the duration from the date of first PR or better to the date of first PD or death due to any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Date of first PR or better to the date of first PD or death due to any cause, whichever occurs first (up to 25 months)

  13. Combination Therapy (Arms: A, B and C): Disease Control Rate (DCR)

    DCR was calculated as the percentage of participants for whom the best overall response (BOR) was determined as CR, PR, or at least 12 continuous weeks of stable disease as assessed by RECIST v1.1 (Arms A, C), and iRECIST (Arm B), before Investigator had determined PD or initiating a new antineoplastic therapy. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 25 months

  14. Combination Therapy (Arms: A, B and C): Overall Survival (OS)

    OS was defined as time since the starting date of the combination therapy until death due to any cause.

    Time frame: Time since the starting date of combination therapy until death due to any cause (up to 25 months)

  15. Monotherapy: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    AE Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.

    Time frame: From start of study drug administration up to survival follow-up (up to 4 months)

  16. Combination Therapy (Arms: A and B): Number of Participants With TEAEs

    AE: Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.

    Time frame: From start of study drug administration up to survival follow-up (up to 25 months)

  17. Combination Therapy (Arm C): Percentage of Participants With ORR as Assessed by RECIST 1.1

    ORR was defined as the proportion of participants who achieve an Investigator-determined BOR of PR or CR as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 25 months

07

Results

Posted Oct 9, 2026
Limitations and caveats
The Combination therapy portion of the study was terminated prior to full enrollment for futility. Enrollment was halted as preliminary antitumor activity of selinexor was assessed by the Sponsor to be insufficiently competitive compared to currently available or anticipated future treatments.

Participant flow

A total of 80 participants were enrolled. Of these, 79 participants received treatment (35 received monotherapy, and 44 received combination therapy). After completing 4 months of monotherapy treatment, participants from the normal hepatic function arm were transitioned to the combination therapy (4 into NSCLC Arm A and 15 into CRC Arm B) to continue the treatment, as planned in the protocol.

Monotherapy: (Up to 4 Months)
Participant flow — Monotherapy: (Up to 4 Months)
MilestoneMonotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B)Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A)Monotherapy: Moderate Hepatic Function (Tablet A Only)Monotherapy: Severe Hepatic Function (Tablet A Only)Combination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
Started1111760000
Participants treated during monotherapy1111760000
Completed109000000
Not completed12760000
Withdrew: Clinical progression11000000
Withdrew: Death00130000
Withdrew: Not eligible for combination therapy01000000
Withdrew: Physician decision00010000
Withdrew: Progressive disease00500000
Withdrew: Withdrawal by subject00110000
Withdrew: Other00010000
Combination Therapy: (Up to 25 Months)
Participant flow — Combination Therapy: (Up to 25 Months)
MilestoneMonotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B)Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A)Monotherapy: Moderate Hepatic Function (Tablet A Only)Monotherapy: Severe Hepatic Function (Tablet A Only)Combination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
Started0000173862
Unique participants in combination therapy0000132362
Participants from monotherapy: normal hepatic function (tablet a first, then tablet b)00002800
Participants from monotherapy: normal hepatic function (tablet b first, then tablet a)00002700
Completed00000000
Not completed0000173862
Withdrew: Adverse event00004200
Withdrew: Clinical progression00004700
Withdrew: Physician decision00000200
Withdrew: Progressive disease000052100
Withdrew: Withdrawal by subject00003410
Withdrew: Other00001200
Withdrew: Death00000052

Outcome measures

PrimaryMonotherapy: Area Under the Concentration-Time Curve From Time Zero to Time of Last Concentration (AUC 0-t) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

AUC0-t was defined as the total-drug area under the concentration-time curve from time zero to time of last concentration measured.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Monotherapy: Area Under the Concentration-Time Curve From Time Zero to Time of Last Concentration (AUC 0-t) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
hour*nanograms per milliliter (h*ng/mL)Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Area Under the Concentration-Time Curve From Time Zero to Time of Last Concentration (AUC 0-t) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment6830 ± 28.86920 ± 27.22380 ± 24.03860 ± 22.4
PrimaryMonotherapy: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-Inf) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated), calculated as AUC0-last + Ct/λ, where: Ct = the last quantifiable concentration and λ is terminal elimination rate constant.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · h*ng/mL
Monotherapy: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-Inf) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
h*ng/mLMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-Inf) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment6880 ± 28.76980 ± 27.12270 ± 16.34060 ± 24.4
PrimaryMonotherapy: Maximum Plasma Concentration (Cmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

Cmax was defined as maximum observed plasma total-drug concentration of selinexor.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Monotherapy: Maximum Plasma Concentration (Cmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
nanograms per milliliter (ng/mL)Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Maximum Plasma Concentration (Cmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment782 ± 40.8813 ± 25.6272 ± 36.4372 ± 42.1
PrimaryCombination Therapy (Arms: A and B): Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

Overall response rate (ORR) was defined as the percentage of participants who achieved an Investigator-determined best overall response (BOR) of partial response (PR) or complete response (CR) as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants who achieved ORR were reported.

Time frame:
Up to 25 months
Reported as:
Number · Percentage of participants
Combination Therapy (Arms: A and B): Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Percentage of participantsCombination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + Pembrolizumab
Combination Therapy (Arms: A and B): Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)11.8 (1.5 to 36.4)0 (0 to 0)
PrimaryCombination Therapy (Arm C): Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Adverse event (AE): Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.

Time frame:
From start of study drug administration up to survival follow-up (up to 25 months)
Reported as:
Count of participants · Participants
Combination Therapy (Arm C): Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
Combination Therapy (Arm C): Number of Participants With Treatment-emergent Adverse Events (TEAEs)62
SecondaryMonotherapy: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

Tmax was defined as time to the maximum observed concentration of selinexor.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Median · hours
Monotherapy: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
hoursMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment4.00 (1.58 to 9.92)2.92 (0.25 to 5.83)5.93 (1.45 to 10.00)5.08 (3.08 to 7.75)
SecondaryMonotherapy: Terminal Elimination Rate Constant (Lambda z) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

Lambda z was defined as the terminal elimination rate constant of selinexor.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · liter per hour (l/h)
Monotherapy: Terminal Elimination Rate Constant (Lambda z) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
liter per hour (l/h)Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Terminal Elimination Rate Constant (Lambda z) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment0.101 ± 19.30.106 ± 28.60.124 ± 29.80.128 ± 50.3
SecondaryMonotherapy: Terminal Half-Life (t1/2) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

t1/2 was defined as the terminal elimination half-life of selinexor.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · hour
Monotherapy: Terminal Half-Life (t1/2) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
hourMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Terminal Half-Life (t1/2) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment6.88 ± 19.36.57 ± 28.65.57 ± 29.85.43 ± 50.3
SecondaryMonotherapy: Apparent Clearance (CL/F) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

CL/F was defined as the apparent clearance of selinexor.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · L/h
Monotherapy: Apparent Clearance (CL/F) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
L/hMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Apparent Clearance (CL/F) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment14.5 ± 28.714.3 ± 27.117.6 ± 16.39.86 ± 24.4
SecondaryMonotherapy: Apparent Volume of Distribution (Vd/F) of Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment

Vd/f was defined as the apparent volume of distribution, calculated as Dose/ (λz\*AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · liter
Monotherapy: Apparent Volume of Distribution (Vd/F) of Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
literMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 X 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Apparent Volume of Distribution (Vd/F) of Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment144 ± 39.2136 ± 45.0142 ± 41.577.2 ± 24.2
SecondaryMonotherapy: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma Protein

Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. Mean percent fraction unbound of selinexor (Tablet A) in plasma, calculated by averaging the percent fraction unbound measurements obtained at 3 and 8 hours post-dose on Days 1 and 8.

Time frame:
At 3 and 8 hours post-dose on Days 1 and 8
Reported as:
Mean · Percent unbound
Monotherapy: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma Protein
Percent unboundMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma Protein4.19 ± 0.9185.33 ± 1.114.4 ± 0.505
SecondaryMonotherapy: Maximum Free-Drug Concentration (Cmax,u) of Free Selinexor (Tablet A) in Plasma

Cmax,u was defined as the maximum observed free-drug concentration of Selinexor, calculated as Cmax \* Fu.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · ng/mL
Monotherapy: Maximum Free-Drug Concentration (Cmax,u) of Free Selinexor (Tablet A) in Plasma
ng/mLMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Maximum Free-Drug Concentration (Cmax,u) of Free Selinexor (Tablet A) in Plasma34.5 ± 46.514.2 ± 38.616.3 ± 51.8
SecondaryMonotherapy: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Free Selinexor (Tablet A) in Plasma

AUCu was defined as free-drug area under the concentration-time curve from time zero to infinity (extrapolated), calculated as (AUC0-last + Ct/λz) \* Fu, where: Ct = the last observed nonzero concentration.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · h*ng/mL
Monotherapy: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Free Selinexor (Tablet A) in Plasma
h*ng/mLMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Free Selinexor (Tablet A) in Plasma297 ± 39.6113 ± 18.7184 ± 29.5
SecondaryMonotherapy: Apparent Free-drug Clearance (CLu/F) of Free Selinexor (Tablet A) in Plasma

CLu/F was defined as the apparent free-drug clearance of selinexor.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · L/h
Monotherapy: Apparent Free-drug Clearance (CLu/F) of Free Selinexor (Tablet A) in Plasma
L/hMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Apparent Free-drug Clearance (CLu/F) of Free Selinexor (Tablet A) in Plasma336 ± 39.6353 ± 18.7217 ± 29.5
SecondaryMonotherapy: Apparent Free-drug Volume of Distribution (Vu/F) of Free Selinexor (Tablet A) in Plasma

Vu/F was defined as the apparent free-drug volume of distribution of selinexor.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · liter
Monotherapy: Apparent Free-drug Volume of Distribution (Vu/F) of Free Selinexor (Tablet A) in Plasma
literMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 X 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Apparent Free-drug Volume of Distribution (Vu/F) of Free Selinexor (Tablet A) in Plasma3170 ± 37.92840 ± 36.61700 ± 22.2
SecondaryCombination Therapy (Arms: A, B and C): Progression-free Survival (PFS)

PFS was defined as the time from the starting date of the combination therapy until the date of first progressive disease (PD) determined by PI per Response Evaluation Criteria in Solid Tumors (RECIST) for Arm A and B or Immunotherapeutic Response Evaluation Criteria in Solid Tumors (iRECIST) for Arm C, or death due to any cause, whichever occurred first.

Time frame:
Time from starting date of combination therapy until the date of first PD or death due to any case, whichever occurs first (up to 25 months)
Reported as:
Median · months
Combination Therapy (Arms: A, B and C): Progression-free Survival (PFS)
monthsCombination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
Combination Therapy (Arms: A, B and C): Progression-free Survival (PFS)5.78 (3.15 to NA)1.97 (1.91 to 3.94)1.86 (1.54 to NA)2.76 (1.71 to NA)
SecondaryCombination Therapy (Arms: A, B and C): Duration of Response (DOR)

DOR was defined for participants with partial response (PR) or complete response (CR) as the duration from the date of first PR or better to the date of first PD or death due to any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Date of first PR or better to the date of first PD or death due to any cause, whichever occurs first (up to 25 months)
Reported as:
Median · months
Combination Therapy (Arms: A, B and C): Duration of Response (DOR)
monthsCombination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
Combination Therapy (Arms: A, B and C): Duration of Response (DOR)14.49 (NA to NA)———
SecondaryCombination Therapy (Arms: A, B and C): Disease Control Rate (DCR)

DCR was calculated as the percentage of participants for whom the best overall response (BOR) was determined as CR, PR, or at least 12 continuous weeks of stable disease as assessed by RECIST v1.1 (Arms A, C), and iRECIST (Arm B), before Investigator had determined PD or initiating a new antineoplastic therapy. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 25 months
Reported as:
Number · percentage of participants
Combination Therapy (Arms: A, B and C): Disease Control Rate (DCR)
percentage of participantsCombination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
Combination Therapy (Arms: A, B and C): Disease Control Rate (DCR)58.8 (32.9 to 81.6)28.9 (15.4 to 45.9)0 (0 to 0)50 (1.3 to 98.7)
SecondaryCombination Therapy (Arms: A, B and C): Overall Survival (OS)

OS was defined as time since the starting date of the combination therapy until death due to any cause.

Time frame:
Time since the starting date of combination therapy until death due to any cause (up to 25 months)
Reported as:
Median · months
Combination Therapy (Arms: A, B and C): Overall Survival (OS)
monthsCombination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
Combination Therapy (Arms: A, B and C): Overall Survival (OS)6.01 (5.49 to NA)8.25 (7.03 to 11.70)4.76 (4.14 to NA)6.83 (5.06 to NA)
SecondaryMonotherapy: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

AE Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.

Time frame:
From start of study drug administration up to survival follow-up (up to 4 months)
Reported as:
Count of participants · Participants
Monotherapy: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic FunctionMonotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Monotherapy: Number of Participants With Treatment-emergent Adverse Events (TEAEs)91174
SecondaryCombination Therapy (Arms: A and B): Number of Participants With TEAEs

AE: Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.

Time frame:
From start of study drug administration up to survival follow-up (up to 25 months)
Reported as:
Count of participants · Participants
Combination Therapy (Arms: A and B): Number of Participants With TEAEs
ParticipantsCombination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + Pembrolizumab
Combination Therapy (Arms: A and B): Number of Participants With TEAEs1737
SecondaryCombination Therapy (Arm C): Percentage of Participants With ORR as Assessed by RECIST 1.1

ORR was defined as the proportion of participants who achieve an Investigator-determined BOR of PR or CR as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 25 months
Reported as:
Number · percentage of participants
Combination Therapy (Arm C): Percentage of Participants With ORR as Assessed by RECIST 1.1
percentage of participantsCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
Combination Therapy (Arm C): Percentage of Participants With ORR as Assessed by RECIST 1.10 (0 to 0)0 (0 to 0)

Adverse events

Collected over Monotherapy: From start of study drug administration (Day 1) up to survival follow-up (up to 4 months); Combination therapy: From start of study drug administration (Day 1) up to survival follow-up (up to 25 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function1/11 (9.1%)4/11 (36.4%)9/11 (81.8%)
Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function1/11 (9.1%)1/11 (9.1%)11/11 (100%)
Monotherapy: Moderate Hepatic Function (Tablet A Only)3/7 (42.9%)5/7 (71.4%)7/7 (100%)
Monotherapy: Severe Hepatic Function (Tablet A Only)5/6 (83.3%)1/6 (16.7%)4/6 (66.7%)
Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel11/17 (64.7%)11/17 (64.7%)17/17 (100%)
Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab30/38 (78.9%)10/38 (26.3%)37/38 (97.4%)
Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)5/6 (83.3%)2/6 (33.3%)6/6 (100%)
Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)2/2 (100%)1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Moderate Hepatic Function (Tablet A Only)Monotherapy: Severe Hepatic Function (Tablet A Only)Combination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
Deep vein thrombosisVascular disorders0/110/110/70/60/170/380/61/2
PyrexiaGeneral disorders1/110/110/70/60/170/382/60/2
Upper gastrointestinal haemorrhageGastrointestinal disorders0/110/110/71/60/170/380/60/2
Respiratory tract infection viralInfections and infestations0/110/110/71/60/170/380/60/2
Febrile neutropeniaBlood and lymphatic system disorders0/110/110/70/62/170/381/60/2
HypotensionVascular disorders0/110/110/70/60/170/381/60/2
CholangitisHepatobiliary disorders0/110/111/70/60/170/380/60/2
CholecystitisHepatobiliary disorders0/110/111/70/60/170/380/60/2
Device related infectionInfections and infestations0/110/111/70/60/170/380/60/2
SepsisInfections and infestations0/110/111/70/60/171/380/60/2
Most frequent other events
Showing 10 of 144
Most frequent other events
EventMonotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic FunctionMonotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic FunctionMonotherapy: Moderate Hepatic Function (Tablet A Only)Monotherapy: Severe Hepatic Function (Tablet A Only)Combination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
VomitingGastrointestinal disorders3/118/111/71/64/1711/381/61/2
NauseaGastrointestinal disorders6/117/113/72/68/1721/384/61/2
AnaemiaBlood and lymphatic system disorders2/111/113/70/69/177/381/60/2
Decreased appetiteMetabolism and nutrition disorders2/113/113/71/69/1717/383/61/2
LeukocytosisBlood and lymphatic system disorders0/110/110/70/60/170/380/61/2
NeutrophiliaBlood and lymphatic system disorders0/110/110/70/60/170/380/61/2
Abdominal painGastrointestinal disorders0/110/113/70/61/174/382/61/2
AscitesGastrointestinal disorders0/110/110/70/60/171/381/61/2
DyspepsiaGastrointestinal disorders0/111/110/70/62/170/380/61/2
FatigueGeneral disorders1/111/112/70/67/1717/383/60/2

Baseline characteristics

Baseline characteristics were summarized for all unique enrolled participants who received monotherapy and combination therapy.

Age, Customized
Age, Customized(Participants)Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B)Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A)Monotherapy: Moderate Hepatic Function (Tablet A Only)Monotherapy: Severe Hepatic Function (Tablet A Only)Combination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)Total
18 - 504314042119
51 - 6415422134132
65 - 744120850020
≥75220031008
Sex: Female, Male
Sex: Female, Male(Participants)Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B)Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A)Monotherapy: Moderate Hepatic Function (Tablet A Only)Monotherapy: Severe Hepatic Function (Tablet A Only)Combination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)Total
Female35134132031
Male86639104248
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B)Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A)Monotherapy: Moderate Hepatic Function (Tablet A Only)Monotherapy: Severe Hepatic Function (Tablet A Only)Combination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)Total
Hispanic or Latino000000000
Not Hispanic or Latino11117613236279
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B)Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A)Monotherapy: Moderate Hepatic Function (Tablet A Only)Monotherapy: Severe Hepatic Function (Tablet A Only)Combination Therapy: NSCLC Arm A: Selinexor + DocetaxelCombination Therapy: CRC Arm B: Selinexor + PembrolizumabCombination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)Total
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American000001001
White11117613226278
More than one race000000000
Unknown or Not Reported000000000
08

Study locations

11 sites
  • University Hospital Assuta Ashdod
    Ashdod, 7747629, Israel
  • Soroka University Medical Center
    Beersheba, 84101, Israel
  • Oncology Department Hillel Yaffe Medical Center
    Hadera, 38100, Israel
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Shaarei Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Hadassah Ein Karem University Hospital
    Jerusalem, 91120, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Galilee Medical Center
    Nahariya, 22100, Israel
  • Rabin Medical Center
    Petah Tikva, 49100, Israel
  • Tel-Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Sheba Medical Center
    Tel Litwinsky, 5265601, Israel
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Jul 2024, 53 months.

Results were first posted in Oct 2026, 2 years 2 months after primary completion.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 53 months is close to that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

Start moved once since we started tracking on Sep 25, 2026: Jan 2020 → Feb 2020, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2020
First posted
Feb 5, 2020
StartActual
Feb 9, 2020was Jan 2020
Primary completionActual
Jul 31, 2024
CompletionActual
Jul 31, 2024
Results first posted
Oct 9, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 9, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 Israel)
  • Soroka University Medical Center · Beersheba, Israel
  • Rabin Medical Center · Petah Tikva, Israel
  • Sheba Medical Center · Tel Litwinsky, Israel
Show 3 removed
  • Soroka University Medical Center · Beer-Sheva, Israel
  • Rabin Medical Center · Petach Tikva, Israel
  • Sheba Medical Center · Tel-Hashomer, Israel
Oct 9, 2026
Start date
Jan 14, 2020→Feb 9, 2020
Oct 9, 2026
Enrollment
126→80
Oct 9, 2026
Eligibility
11 criteria edited, 3 added, 1 removed
What changed in the criteria
  • EditedHave histologically confirmed solid tumor (any type of advanced or metastatic solid tumor for the Hepatic Impairment Arm of the Monotherapy Part), advanced or metastatic NSCLC or CRC and evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1 or iRECIST criteria, as applicable).
  • EditedWilling to provide signed written informed consent in accordance with federal, local, and institutional guidelines and comply with all requirements of the study.
  • EditedFemale patientpatients of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective (dual methods of) contraception throughout the study and for 4 months following the last dose of study drug (childbearing potential excludes: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy or hysterectomy); and male patients must use an effective barrier method of contraception throughout the study and for 4 months following the last dose of study drug if sexually active. Male patients must agree not to donate sperm during the study treatment period.
  • EditedHave received at least 1 line of systemic anticancer treatment unless there is no first-line standard of care therapy or standard of care therapy is contraindicated (adjuvant or neoadjuvant therapy is not counted as one line of systemic therapy). Patients must have failed prior standard curative therapy for their disease, must be intolerant to or be ineligible for any potentially curative approved treatment, irrespective of line of therapy.
  • EditedFor S20-100 or S100-20 arms: absolute neutrophil count (ANC) <1.5 × 10910\^9/liter (L); platelet count (PLT) <100 × 10910\^9/L; or hemoglobin (Hb) <910 gram per deciliter (g/dL).
  • AddedFor Arms A-C: ANC <1.5 × 10\^9/L; PLT <100 × 10\^9/L; or Hb <10 g/dL.
  • EditedHave inadequate renal function defined as a calculated creatinine clearance (CrCl) of: a. all patients: <20 mL/min using the formula of Cockcroft and Gault.
  • AddedAll patients: on Day 1 dosing.
  • EditedNot recovered from major surgery ≤21 days for Arms A, B, and C prior to Day 1 dosing. Minor procedures, such as biopsies, dental work, or placement of a port or intravenous (IV) line for infusion are permitted.
  • EditedSerious active psychiatric or active medical condition that could interfere with participation in the study or in the opinion of the Investigator would make study involvement unreasonably hazardous for Arms A-C.
  • RemovedIn the opinion of the Investigator, patients who are below their ideal body weight and would be unduly impacted by changes in their weight.
  • EditedKnown allergy to selinexor (all patients), docetaxel (NSCLC Arm A only), pembrolizumab (CRC arm B only), OR 5-FU, leucovorin, or irinotecan (CRC Arm C only).
  • AddedFemale patients who are pregnant or breastfeeding.
  • EditedFemale patients who are pregnant or breastfeeding. For Monotherapy Part only (BA/BE and HI arms):
  • EditedFor MHI and SHI arms: ANC <1 × 10910\^9/L; PLT <75 × 10910\^9/L; or Hb <8 g/dL.
Oct 9, 2026
Primary outcomes
5 edited
What changed in the outcomes
  • EditedMonotherapy Period: Area Under the Concentration-Time Curve fromFrom Time Zero to Time of Last Concentration (AUC 0-t) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic FunctionImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Area Under the Concentration-Time Curve fromFrom Time Zero Extrapolated to Infinity (AUC 0-infInf) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic FunctionImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Maximum Plasma Concentration (Cmax) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic FunctionImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedCombination Therapy Period(Arms: Arm A and B): Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to 36 months → Up to 25 months
  • EditedCombination Therapy Period: (Arm C): Number of PatientsParticipants With Treatment-emergent Adverse Events (AEsTEAEs)Time frame: From start of study drug administration up to survival follow-up (Up to 36 months) → From start of study drug administration up to survival follow-up (up to 25 months)
Oct 9, 2026
Documents
Secondary outcomes
13 edited, 4 added, 4 removed
What changed in the outcomes
  • EditedMonotherapy Period: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Terminal Elimination Rate Constant (Lambda z) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Terminal Half-Life (t1/2) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Apparent Clearance (CL/F) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Apparent Volume of Distribution (Vd/F) of Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period:: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma ProteinTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8 → At 3 and 8 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Maximum Free-Drug Concentration (CmaxuCmax,u) of Free Selinexor (Tablet A) in PlasmaTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Free Selinexor (Tablet A) in PlasmaTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Apparent Free-drug Clearance (CLu/F) of Free Selinexor (Tablet A) in PlasmaTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedMonotherapy Period: Apparent Free-drug Volume of Distribution (Vu/F) of Free Selinexor (Tablet A) in PlasmaTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
  • EditedCombination Therapy Period: Overall Survival (OS(Arm C): Arms A and CPercentage of Participants With ORR as Assessed by RECIST 1.1 and Arm B as Assessed by iRECISTTime frame: Up to 36 months → Up to 25 months
  • EditedMonotherapy Period: Number of PatientsParticipants With Treatment-emergent Adverse Events (AEsTEAEs)Time frame: From start of study drug administration up to survival follow-up (up to 36 months) → From start of study drug administration up to survival follow-up (up to 4 months)
  • EditedCombination Therapy Period(Arms: Arm A and B): Number of PatientsParticipants With Adverse Events (AEs)TEAEsTime frame: From start of study drug administration up to survival follow-up (up to 36 months) → From start of study drug administration up to survival follow-up (up to 25 months)
  • AddedCombination Therapy (Arms: A, B and C): Progression-free Survival (PFS)Time frame: Time from starting date of combination therapy until the date of first PD or death due to any case, whichever occurs first (up to 25 months)
  • AddedCombination Therapy (Arms: A, B and C): Duration of Response (DOR)Time frame: Date of first PR or better to the date of first PD or death due to any cause, whichever occurs first (up to 25 months)
  • AddedCombination Therapy (Arms: A, B and C): Disease Control Rate (DCR)Time frame: Up to 25 months
  • AddedCombination Therapy (Arms: A, B and C): Overall Survival (OS)Time frame: Time since the starting date of combination therapy until death due to any cause (up to 25 months)
  • RemovedCombination Therapy Period: Progression-free Survival (PFS): Arms A and C as Assessed by RECIST 1.1 and Arm B as Assessed by iRECISTTime frame: Up to 36 months
  • RemovedCombination Therapy Period: Duration of Response (DOR): Arms A and C as Assessed by RECIST 1.1 and Arm B as Assessed by iRECISTTime frame: Up to 36 months
  • RemovedCombination Therapy Period: Disease Control Rate (DCR): Arms A and C: as Assessed by RECIST 1.1 and Arm B as Assessed by iRECISTTime frame: Up to 36 months
  • RemovedCombination Therapy Period: Arm C: Overall Response Rate (ORR) as Assessed by RECIST 1.1Time frame: Up to 36 months
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Results posted
    3 sites added, 3 sites removed
    Show 3 added (3 Israel)
    • Soroka University Medical Center · Beersheba, Israel
    • Rabin Medical Center · Petah Tikva, Israel
    • Sheba Medical Center · Tel Litwinsky, Israel
    Show 3 removed
    • Soroka University Medical Center · Beer-Sheva, Israel
    • Rabin Medical Center · Petach Tikva, Israel
    • Sheba Medical Center · Tel-Hashomer, Israel
    Start date Jan 14, 2020→Feb 9, 2020
    Enrollment 126→80
    Eligibility 11 criteria edited, 3 added, 1 removed
    What changed in the criteria
    • EditedHave histologically confirmed solid tumor (any type of advanced or metastatic solid tumor for the Hepatic Impairment Arm of the Monotherapy Part), advanced or metastatic NSCLC or CRC and evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1 or iRECIST criteria, as applicable).
    • EditedWilling to provide signed written informed consent in accordance with federal, local, and institutional guidelines and comply with all requirements of the study.
    • EditedFemale patientpatients of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective (dual methods of) contraception throughout the study and for 4 months following the last dose of study drug (childbearing potential excludes: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy or hysterectomy); and male patients must use an effective barrier method of contraception throughout the study and for 4 months following the last dose of study drug if sexually active. Male patients must agree not to donate sperm during the study treatment period.
    • EditedHave received at least 1 line of systemic anticancer treatment unless there is no first-line standard of care therapy or standard of care therapy is contraindicated (adjuvant or neoadjuvant therapy is not counted as one line of systemic therapy). Patients must have failed prior standard curative therapy for their disease, must be intolerant to or be ineligible for any potentially curative approved treatment, irrespective of line of therapy.
    • EditedFor S20-100 or S100-20 arms: absolute neutrophil count (ANC) <1.5 × 10910\^9/liter (L); platelet count (PLT) <100 × 10910\^9/L; or hemoglobin (Hb) <910 gram per deciliter (g/dL).
    • AddedFor Arms A-C: ANC <1.5 × 10\^9/L; PLT <100 × 10\^9/L; or Hb <10 g/dL.
    • EditedHave inadequate renal function defined as a calculated creatinine clearance (CrCl) of: a. all patients: <20 mL/min using the formula of Cockcroft and Gault.
    • AddedAll patients: on Day 1 dosing.
    • EditedNot recovered from major surgery ≤21 days for Arms A, B, and C prior to Day 1 dosing. Minor procedures, such as biopsies, dental work, or placement of a port or intravenous (IV) line for infusion are permitted.
    • EditedSerious active psychiatric or active medical condition that could interfere with participation in the study or in the opinion of the Investigator would make study involvement unreasonably hazardous for Arms A-C.
    • RemovedIn the opinion of the Investigator, patients who are below their ideal body weight and would be unduly impacted by changes in their weight.
    • EditedKnown allergy to selinexor (all patients), docetaxel (NSCLC Arm A only), pembrolizumab (CRC arm B only), OR 5-FU, leucovorin, or irinotecan (CRC Arm C only).
    • AddedFemale patients who are pregnant or breastfeeding.
    • EditedFemale patients who are pregnant or breastfeeding. For Monotherapy Part only (BA/BE and HI arms):
    • EditedFor MHI and SHI arms: ANC <1 × 10910\^9/L; PLT <75 × 10910\^9/L; or Hb <8 g/dL.
    Primary outcomes 5 edited
    What changed in the outcomes
    • EditedMonotherapy Period: Area Under the Concentration-Time Curve fromFrom Time Zero to Time of Last Concentration (AUC 0-t) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic FunctionImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Area Under the Concentration-Time Curve fromFrom Time Zero Extrapolated to Infinity (AUC 0-infInf) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic FunctionImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Maximum Plasma Concentration (Cmax) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic FunctionImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedCombination Therapy Period(Arms: Arm A and B): Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to 36 months → Up to 25 months
    • EditedCombination Therapy Period: (Arm C): Number of PatientsParticipants With Treatment-emergent Adverse Events (AEsTEAEs)Time frame: From start of study drug administration up to survival follow-up (Up to 36 months) → From start of study drug administration up to survival follow-up (up to 25 months)
    Secondary outcomes 13 edited, 4 added, 4 removed
    What changed in the outcomes
    • EditedMonotherapy Period: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Terminal Elimination Rate Constant (Lambda z) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Terminal Half-Life (t1/2) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Apparent Clearance (CL/F) of Total Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Apparent Volume of Distribution (Vd/F) of Selinexor in Patients withParticipants With Normal, Moderate and Severe Hepatic ImpairmentTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period:: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma ProteinTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8 → At 3 and 8 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Maximum Free-Drug Concentration (CmaxuCmax,u) of Free Selinexor (Tablet A) in PlasmaTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Free Selinexor (Tablet A) in PlasmaTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Apparent Free-drug Clearance (CLu/F) of Free Selinexor (Tablet A) in PlasmaTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedMonotherapy Period: Apparent Free-drug Volume of Distribution (Vu/F) of Free Selinexor (Tablet A) in PlasmaTime frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
    • EditedCombination Therapy Period: Overall Survival (OS(Arm C): Arms A and CPercentage of Participants With ORR as Assessed by RECIST 1.1 and Arm B as Assessed by iRECISTTime frame: Up to 36 months → Up to 25 months
    • EditedMonotherapy Period: Number of PatientsParticipants With Treatment-emergent Adverse Events (AEsTEAEs)Time frame: From start of study drug administration up to survival follow-up (up to 36 months) → From start of study drug administration up to survival follow-up (up to 4 months)
    • EditedCombination Therapy Period(Arms: Arm A and B): Number of PatientsParticipants With Adverse Events (AEs)TEAEsTime frame: From start of study drug administration up to survival follow-up (up to 36 months) → From start of study drug administration up to survival follow-up (up to 25 months)
    • AddedCombination Therapy (Arms: A, B and C): Progression-free Survival (PFS)Time frame: Time from starting date of combination therapy until the date of first PD or death due to any case, whichever occurs first (up to 25 months)
    • AddedCombination Therapy (Arms: A, B and C): Duration of Response (DOR)Time frame: Date of first PR or better to the date of first PD or death due to any cause, whichever occurs first (up to 25 months)
    • AddedCombination Therapy (Arms: A, B and C): Disease Control Rate (DCR)Time frame: Up to 25 months
    • AddedCombination Therapy (Arms: A, B and C): Overall Survival (OS)Time frame: Time since the starting date of combination therapy until death due to any cause (up to 25 months)
    • RemovedCombination Therapy Period: Progression-free Survival (PFS): Arms A and C as Assessed by RECIST 1.1 and Arm B as Assessed by iRECISTTime frame: Up to 36 months
    • RemovedCombination Therapy Period: Duration of Response (DOR): Arms A and C as Assessed by RECIST 1.1 and Arm B as Assessed by iRECISTTime frame: Up to 36 months
    • RemovedCombination Therapy Period: Disease Control Rate (DCR): Arms A and C: as Assessed by RECIST 1.1 and Arm B as Assessed by iRECISTTime frame: Up to 36 months
    • RemovedCombination Therapy Period: Arm C: Overall Response Rate (ORR) as Assessed by RECIST 1.1Time frame: Up to 36 months
    + 6 other changes: index terms, verification date, registry dates, oversight details, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04256707
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Feb 9, 2020
Primary completion
Jul 31, 2024
Completion
Jul 31, 2024
Results posted
Oct 9, 2026
Last update
Oct 9, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion